The Interconnect team is here to help

Your patient’s Care Manager team is your primary contact, but they are supported by a network.

To keep things moving smoothly, you may hear from others on the team along the way.

Care Manager Team

Dedicated resource assigned to
your office and patients. Assists with benefits investigations and provides information about prior authorizations.

  • Territory Business Managera

    In-office resource for questions
    about Alfasigma treatment

  • Field Reimbursement Managera

    Dedicated access and reimbursement
    resource for your office

  • Director of Strategic Accountsa

    Resource that works with payers
    to help facilitate coverage

aTerritory Business Manager, Field Reimbursement Manager, and Director of Strategic Accounts are also Alfasigma Team Members.

You are now leaving Interconnect

Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

Interconnect's website is being temporarily maintained and is no longer fully functional for enrollment purposes due to the withdrawal of OCALIVA.

Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

For all other inquiries please contact: info@interceptpharma.com